



IPW

PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

12

Application Number	10/574,163 ✓
Filing Date	June 15, 2006
First Named Inventor	LIU, Jin
Art Unit	TBD
Examiner Name	TBD
Attorney Docket Number	8028-005-US

ENCLOSURES (Check all that apply)

- | | | |
|---|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement

<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____
<input type="checkbox"/> Landscape Table on CD | <input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
1. Self-addressed, stamped postcard
2. Forms PTO/SB/08A & B
3. Copies of reference as cited |
|---|---|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	Catalyst Law Group, APC		
Signature			
Printed name	Michael B. Farber, Esq.		
Date	June 15, 2006	Reg. No.	32,612

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Sara Hare	Date	June 15, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/574,163	
	Filing Date	March 29, 2006
	First Named Inventor	LIU, Jin
	Art Unit	TBD
	Examiner Name	TBD
Attorney Docket Number	8028-005-US	

Sheet 1 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		J.B. MILLS et al., "Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line," J. Pharm. Exp. Therap. 309: 303-309 (2003).	
/N.A./		G. LUO et al., "CYP3A4 Induction by Drugs: Correlation Between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression...", Drug Metab. Dispos. 30: 795-804 (2002).	
/N.A./		A. MADAN et al., "Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes, Drug Metab. Dispos. 31: 421-431 (2003).	
/N.A./		G.T. TUCKER et al., "Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential - Toward...", Pharmaceutic. Res. 18: 1071-1080 (2001).	
/N.A./		T.D. Bjorsson et al., "The Conduct of in Vitro and in Vivo Drug-Drug Interaction Studies: A PhRMA Perspective," J. Clin. Pharmacol. 43: 443-469 (2003).	
/N.A./		F. Bost et al., "Inter-Alpha-Trypsin Inhibitor Proteoglycan Family-a Group of Proteins Binding and Stabilizing the Extracellular Matrix," Eur. J Biochem. 252: 339-346 (1998).	
/N.A./		S. Yang et al., "Administration of Human Inter-α-Inhibitors Maintains Hemodynamic Stability and Improves Survival During Sepsis," Crit. Care Med. 30: 617-22 (2002).	
/N.A./		K.E. Thummel & G.R. Wilkinson, "In Vitro and In Vivo Drug Interactions Involving Human CYP 3A," Ann. Rev. Pharmacol. Toxicol. 38: 389-430 (1998).	
/N.A./		S. M. Cascio, "Novel Strategies for Immortalization of Human Hepatocytes," Artificial Orgs. 25: 529-538 (2001).	
/N.A./		T. Kuroki & N. Huh, "Why Are Human Cells Resistant to Malignant Cell Transformation in Vitro?," Jpn. J. Cancer Res. 84: 1091-1100 (1993).	

Examiner Signature	/Vera Afremova/	Date Considered	04/16/2008
---------------------------	-----------------	------------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/574,163		
		Filing Date	March 29, 2006		
		First Named Inventor	LIU, Jin		
		Art Unit	TBD		
		Examiner Name	TBD		
Sheet	2	of	3	Attorney Docket Number	8028-005-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/V.A./		H. ZUR HAUSEN, "Oncogenic Herpesviruses" in J. Tooze ed., DNA Tumor Viruses (Rev. Ed. 2, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1981), pp 747-798.	
/V.A./		M. POPOVIC et al., "Transformation of Human Umbilical Cord Blood T-Cells by Human T-Cell Leukemia/Lymphoma Virus (HTLV)," Proc. Natl. Acad. Sci. USA 80:5402-5406 (1983).	
/V.A./		J.A. DIPAOLO et al., "Progressive Changes Induced in Human and Mouse Cells by Human Papillomavirus Type 16 DNA," Cancer Cells 5: 253-257 (1987).	
/V.A./		M.K. PATTERSON, Jr., "Measurement of Growth and Viability of Cells in Culture," Methods Enzymol., 58:141-152 (1979).	
/V.A./		L.H. THOMPSON, "Mutant Isolation," Methods Enzymol. 58: 308-322 (1979).	
/V.A./		S. A. LATT et al., "Microfluorometric Detection of Deoxyribonucleic Acid Replication in Human Metaphase Chromosomes," Proc. Natl. Acad. Sci. USA 70:3395 (1973).	
/V.A./		S. A. LATT, "Fluorometric Detection of Deoxyribonucleic Acid Synthesis; Possibilities for Interfacing Bromodeoxyuridine Dye...", J. Histochem. Cytochem. 25:913-926 (1977).	
/V.A./		P. PERRY & S. WOLFF, "New Giemsa Method for the Differential Staining of Sister Chromatids," Nature 261:156-158 (1974).	
/V.A./		S. WOLFF (1981), "Measurement..." in E.C. Friedberg & P.C. Hanawalt, eds., DNA Repair: A Laboratory Manual of Research..., (Dekker, N.Y., 1981), vol. 1, Part B, pp. 575-586.	
/V.A./		E.G. CORMIER et al., "CD81 Is an Entry Coreceptor for Hepatitis C Virus," Proc. Natl. Acad. Sci. USA 101:7270-7274 (2004).	

Examiner Signature	/Vera Afremova/	Date Considered	04/16/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number 10/574,163

Filing Date March 29, 2006

First Named Inventor LIU, Jin

Art Unit TBD

Examiner Name TBD

Sheet 3 of 3 Attorney Docket Number 8028-005-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/N.A./		J.P. SALIER et al., "The Inter- α -Inhibitor Family: From Structure to Regulation," Biochem. J. 351: 1-9 (1996).	
/N.A./		G. GRYNKIEWICZ et al, "A New Generation of Ca ²⁺ Indicators with Greatly Improved Fluorescence Properties," J. Biol. Chem. 260:3440-3450 (1985).	
/N.A./		E.J. STANBRIDGE et al, "Human Cell Hybrids: Analysis of Transformation and Tumorigenicity," Science 215:252-259 (1982).	
/N.A./		T. TSURIMOTO et al., "Stable Expression and Replication of Hepatitis B Virus Genome in an Integrated State in a Human....," Proc.Natl. Acad. Sci. USA 84:444-448 (1987).	
/N.A./		C.A. BRENNER et al. "Message Amplification Phenotyping (MAPPING): A Technique to Simultaneously Measure Multiple mRNAs from Small....," Biotechniques 7: 1096-1103 (1989).	
/N.A./		Y.P. LIM et al., "Correlation Between Mortality and the Levels of Inter-alpha Inhibitors in Plasma of Severely Septic Patients," J. Infect. Dis. 188:919-926 (2003).	
/N.A./		K. NAWA et al., "Glucocorticoid-Dependent Expression of the Albumin Gene in Adult Rat Hepatocytes," J. Biol. Chem. 261:16883-16888 (1986).	

Examiner
Signature

/Vera Afremova/

Date
Considered

04/16/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.




PATENT
8028-005-US

CERTIFICATE OF MAILING
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Mail Stop: Information Disclosure Statement, P. O. Box 1450, Alexandria, VA 22313-1450.

June 15, 2006
Date of Deposit

Sara Hare
Name of Person Mailing Paper

Signature of Person Mailing Paper

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	Examiner: To Be Assigned
)	
Liu et al.)	Group Art Unit: To Be Assigned
)	
Serial No.: 10/574,163)	
)	Docket No.: 8028-005-US
)	
Filed: March 29, 2006)	Date Mailed: June 15, 2006
)	
For: IMMORTALIZED HEPATOCYTES)	
)	
)	

INFORMATION DISCLOSURE STATEMENT

Mail Stop: Information Disclosure Statement
Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This document is an Information Disclosure Statement to the above-cited patent application.

Attached is at least one form PTO/SB/08A/B listing documents believed relevant to the subject application. The submission of the following information is not intended, nor should it be construed, to constitute an admission that any patent, article, or other information referred to herein is "prior art" unless specifically designated as such. In accordance with 37 C.F.R. § 1.97(b), the filing of this information shall not be construed to mean that a search has been made or that no other material information may exist. Neither should its submission be construed to indicate that a thorough search should not be conducted by the Examiner.

It is believed that this disclosure complies with the requirements of 37 C.F.R. § 1.96, § 1.97, and § 1.98 and the Manual of Patent Examining Procedures § 707.05(b). If for some reason the Examiner considers otherwise, it is respectfully requested that the undersigned be telephoned at (858) 450-0099 x302 so that any deficiencies can be remedied.

This Information Disclosure Statement is being submitted within three months of the filing date of the above-identified patent application. Accordingly, no fee is due for the filing of this Information Disclosure Statement under 37 C.F.R. § 1.97(b)(1).

A copy of each document is enclosed, except for issued United States patents and published United States patent applications pursuant to 37 C.F.R. § 1.98(a)(2)(ii). Some of the documents may have markings thereon. No significance is to be attached to the markings. These documents are not necessarily analogous art. Additionally, the order of the following documents is to be accorded no particular import, as the order thereof is completely fortuitous.

It is respectfully requested that these documents be: (1) fully considered by the Patent and Trademark Office during the prosecution of this application; and (2) represented on any patent which may issue on the application. Applicant respectfully

requests that copies of the forms PTO/SB/08A/B, as considered and initialed by the Examiner, be returned with the next communication.

U.S. Patent No. 5,665,589 to Harris et al., issued on September 9, 1997.

U.S. Patent No. 6,046,050 to Strauss et al., issued on April 4, 2000.

U.S. Patent No. 6,107,043 to Jauregui et al., issued on August 22, 2000.

U.S. Patent No. 6,653,105 to Triglia et al., issued on November 25, 2003.

U.S. Patent Application Publication No. 2002/0045262 by Prachumsri, published on April 18, 2002.

PCT Patent Application Publication No. WO 99/55853 by Fukaya et al., published on November 4, 1999, which describes a novel immortalized hepatic cell line originating in normal human (preferably human fetal) cells, a process for producing this cell line; a method for screening compounds or salts thereof capable of inhibiting or promoting the activity of an enzyme participating in the metabolism of a biological foreign matter in the liver, inhibiting or promoting the expression of a gene encoding an enzyme participating in the metabolism of a biological foreign matter in the liver, or inhibiting or promoting the induction of the expression of a gene encoding an enzyme participating in the metabolism of a biological foreign matter in the liver, the process involving using the above-mentioned cell line. The application further describes compounds capable of inhibiting or promoting the activity of an enzyme participating in the metabolism of a biological foreign matter in the liver, compounds capable of inhibiting or promoting the expression of a gene encoding an enzyme participating in the metabolism of a biological foreign matter in the liver, compounds capable of inhibiting or promoting the induction of the expression of a gene encoding an enzyme participating in the metabolism of a biological foreign matter in the liver, or salts of these compounds

obtained by the above screening method. The cell line is described as useful in, for example, screening compounds having preventive/therapeutic effects on liver failure.

A publication, J.B. Mills et al., "Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line," J. Pharm. Exp. Therap. 309: 303-309 (2003).

A publication, G. Luo et al., "CYP3A4 Induction by Drugs: Correlation Between a Pregnane X Receptor Reporter Gene Assay and CYP3A4 Expression in Human Hepatocytes," Drug Metab. Dispos. 30: 795-804 (2002).

A publication, A. Madan et al., "Effects of Prototypical Microsomal Enzyme Inducers on Cytochrome P450 Expression in Cultured Human Hepatocytes," Drug Metab. Dispos. 31: 421-431 (2003).

A publication, G.T. Tucker et al., "Optimizing Drug Development: Strategies to Assess Drug Metabolism/Transporter Interaction Potential – Toward a Consensus," Pharmaceutic. Res. 18: 1071-1080 (2001).

A publication, T.D. Bjorsson et al., "The Conduct of in Vitro and in Vivo Drug-Drug Interaction Studies: A PhRMA Perspective," J. Clin. Pharmacol. 43: 443-469 (2003).

A publication, F. Bost et al., "Inter-Alpha-Trypsin Inhibitor Proteoglycan Family-a Group of Proteins Binding and Stabilizing the Extracellular Matrix," Eur. J Biochem. 252: 339-346 (1998).

A publication, S. Yang et al., "Administration of Human Inter- α -Inhibitors Maintains Hemodynamic Stability and Improves Survival During Sepsis," Crit. Care Med. 30: 617-22 (2002).

A publication, K.E. Thummel & G.R. Wilkinson, "In Vitro and In Vivo Drug Interactions Involving Human CYP 3A," Ann. Rev. Pharmacol. Toxicol. 38: 389-430 (1998).

A publication, S. M. Cascio, "Novel Strategies for Immortalization of Human Hepatocytes," Artificial Orgs. 25: 529-538 (2001).

A publication, T. Kuroki & N. Huh, "Why Are Human Cells Resistant to Malignant Cell Transformation in Vitro?," Jpn. J. Cancer Res. 84: 1091-1100 (1993).

A publication, H. Zur Hausen, "Oncogenic Herpesviruses" in J. Tooze ed., DNA Tumor Viruses (Rev. Ed. 2, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1981), pp 747-795.

A publication, M. Popovic et al., "Transformation of Human Umbilical Cord Blood T-Cells by Human T-Cell Leukemia/Lymphoma Virus (HTLV)," Proc. Natl. Acad. Sci. USA 80:5402-5406 (1983).

A publication, J.A. DiPaolo et al., "Progressive Changes Induced in Human and Mouse Cells by Human Papillomavirus Type 16 DNA," Cancer Cells 5: 253-257 (1987).

A publication, M.K. Patterson, Jr., "Measurement of Growth and Viability of Cells in Culture," Methods Enzymol., 58:141-152 (1979).

A publication, L.H. Thompson, "Mutant Isolation," Methods Enzymol. 58: 308-322 (1979).

A publication, S. A. Latt et al., "Microfluorometric Detection of Deoxyribonucleic Acid Replication in Human Metaphase Chromosomes," Proc. Natl. Acad. Sci. USA 70:3395 (1973).

A publication, S. A. Latt, "Fluorometric Detection of Deoxyribonucleic Acid Synthesis; Possibilities for Interfacing Bromodeoxyuridine Dye Techniques with Flow Fluorometry," J. Histochem. Cytochem. 25:913-926 (1977).

A publication, P. Perry & S. Wolff, "New Giemsa Method for the Differential Staining of Sister Chromatids," Nature 261:156-158 (1974).

A publication, S. Wolff (1981), "Measurement of Sister Chromatid Exchange in Mammalian Cells" in E.C. Friedberg & P.C. Hanawalt, eds., DNA Repair: A Laboratory Manual of Research Procedures (Dekker, N.Y., 1981), vol. 1, Part B, pp. 575-586.

A publication, E.G. Cormier et al., "CD81 Is an Entry Coreceptor for Hepatitis C Virus," Proc. Natl. Acad. Sci. USA 101:7270-7274 (2004).

A publication, J.P. Salier et al., "The Inter- α -Inhibitor Family: From Structure to Regulation," Biochem. J. 351: 1-9 (1996).

A publication, G. Grynkiewicz et al, "A New Generation of Ca^{2+} Indicators with Greatly Improved Fluorescence Properties," J. Biol. Chem. 260:3440-3450 (1985).

A publication, E.J. Stanbridge et al, "Human Cell Hybrids: Analysis of Transformation and Tumorigenicity," Science 215:252-259 (1982).

A publication, T. Tsurimoto et al., "Stable Expression and Replication of Hepatitis B Virus Genome in an Integrated State in a Human Hepatoma Cell Line Transfected with the Cloned Viral DNA," Proc. Natl. Acad. Sci. USA 84:444-448 (1987).

A publication, C.A. Brenner et al. "Message Amplification Phenotyping (MAPPING): A Technique to Simultaneously Measure Multiple mRNAs from Small Numbers of Cells," Biotechniques 7: 1096-1103 (1989).


A publication, Y.P. Lim et al., "Correlation Between Mortality and the Levels of Inter-alpha Inhibitors in Plasma of Severely Septic Patients," J. Infect. Dis. 188:919-926 (2003).

A publication, K. Nawa et al., "Glucocorticoid-Dependent Expression of the Albumin Gene in Adult Rat Hepatocytes," J. Biol. Chem. 261:16883-16888 (1986).

Respectfully submitted,

Date: June 15, 2006

CATALYST LAW GROUP, APC
9710 Scranton Road, Suite 170
San Diego, California 92121
(858) 450-0099
(858) 450-9834 (Fax)



Michael B. Farber, Ph.D., Esq.
Registration Number: 32,612